CD8A and cancer: Preclinical studies and clinical cohorts have shown that there was a large amount of CD8+ TEXs in tumors, which was closely related to poor clinical outcomes in a variety of cancers (lung cancer, melanoma, liver cancer, etc.)(5, 8–11).